Biologics needed to treat many diseases don’t yet exist.
The opportunity
Many GPCR targets still rely on small molecules with significant clinical limitations. Precise, targeted biologics can change that.
> 400
GPCRs and ion channels implicated in human disease.
> 100
Diseases where GPCRs play a significant role.
~ 34%
of all approved drugs target GPCRs, primarily via small molecules.
Most
GPCR targets have no approved biologics; no ion channels do.
EPITOPE SPECIFICITY
DESIGNED FOR FUNCTION
Agonist
The antibody binds and mimics the natural ligand — triggering downstream G-protein dissociation and intracellular signalling cascades.
Antagonist
The antibody occupies the binding site without activating — preventing endogenous ligands from engaging the receptor and halting signal transduction.
Antiverse combines 10 years of proprietary GPCR data with 240+ exclusive cell lines, creating a closed loop that continuously improves our AI models.
CELL LINE TECHNOLOGY
Our in-house engineered cell lines allow us to screen for GPCR binders in their native context - providing more surface area to successfully bind hidden, complex receptors, and increasing confidence that the hits are conformationally correct.
20x
Higher GPCR expression on Antiverse human cell line vs traditional cell line
Higher receptor density means a more successful screening campaign for challenging targets like GPCRs.
THE DIFFERENCE
Antiverse-engineered stable cell lines precisely overexpress GPCR target receptors, allowing us to discover more antibody clones, without toxicity. By screening in their native context, we avoid the pitfalls of many traditional screening methods.
